Show simple item record

dc.contributor.advisorLeite, Tore
dc.contributor.authorFeratovic, Eldin
dc.contributor.authorLundstrøm, Lars Henrik
dc.date.accessioned2019-02-21T11:09:34Z
dc.date.available2019-02-21T11:09:34Z
dc.date.issued2018
dc.identifier.urihttp://hdl.handle.net/11250/2586720
dc.description.abstractThis thesis investigates initial public offerings (IPOs) at the Nasdaq exchange in the United States during the time period of 2003 – November 17th, 2017. The focus of the thesis will be on the performance, both in the short- and long-run, of companies in the biotechnology industry. Textual analysis will be applied to determine the effect of prospectus sentiment on performance. From our sample of 781 observations, we find an average market-adjusted underpricing of 16.6%. The average market-adjusted underpricing is higher in the biotechnology industry relative to other offerings, but this difference is not statistically significant. For the long-run performance, the offerings in our sample perform 1.6 percentage points better relative to the market. The difference between biotechnology and non-biotechnology is not significant. Our analysis of the IPO prospectuses finds that the companies in the lowest quartile in terms of polarity score of the prospectus summary have less underpricing. Offerings in this quartile perform better in the long-run, while companies in the lower quartile of the risk factors section perform worse.nb_NO
dc.language.isoengnb_NO
dc.subjectfinancial economicsnb_NO
dc.titleInitial public offerings : IPO performance and prospectus sentiment of biotechnology offeringsnb_NO
dc.typeMaster thesisnb_NO
dc.description.localcodenhhmasnb_NO


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record